-
1 week ago | 
optometrytimes.com | Sydney M Crago |Modern Retina |Emily Kaiser Maharjan
The FDA has granted 510(k) clearance to BVI Medical for its glaucoma surgical system, called Leos (Laser Endoscopy Ophthalmic System). Leos is designed to introduce a novel, intuitive Laser ECP procedure that can integrate seamlessly into the surgical workflow. Notably this is the only laser system that lowers intraocular pressure by addressing aqueous humor production in a minimally invasive ab interno procedure.
-
1 week ago | 
optometrytimes.com | Paul Karpecki |Emily Kaiser Maharjan
The landscape of myopia management is evolving rapidly, with growing global awareness and an increasing arsenal of treatment options. In a recent discussion on the FDA's acceptance of Sydnexis's NDA submission for SYD-101, a non-compounded atropine drop indicated for myopia, Paul Karpecki, OD, FAAO, emphasized how the perception of myopia has shifted—from a benign refractive error to a serious medical condition with long-term ocular health implications.
-
1 week ago | 
ophthalmologytimes.com | Emily Kaiser Maharjan
Harrow is expanding its VEVYE Access for All campaign to include patients who use compounded cyclosporine 0.1% (Klarity-C, ImprimisRx) for dry eye and are interested in switching to cyclosporine ophthalmic solution 0.1% (VEVYE, Harrow). With this program, patients who use Klarity-C can convert their prescription to VEVYE for a flat rate of $59 per bottle, including refills.
-
2 weeks ago | 
optometrytimes.com | Emily Kaiser Maharjan
April 10, 2025By Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle. Harrow is expanding its VEVYE Access for All campaign to include patients who use compounded cyclosporine 0.1% (Klarity-C, ImprimisRx) for dry eye and are interested in switching to cyclosporine ophthalmic solution 0.1% (VEVYE, Harrow).
-
4 weeks ago | 
optometrytimes.com | Paul Karpecki |Emily Kaiser Maharjan
The recent FDA acceptance of the new drug application for atropine 0.01% (SYD-101, Sydnexis) marks a significant milestone in the field of myopia management, and Paul Karpecki, OD, FAAO, clinical investigator of the STAR study. SYD-101 is a low-dose atropine formulation designed to slow the progression of myopia in children.
-
1 month ago | 
optometrytimes.com | Nora Lee Cothran |Emily Kaiser Maharjan |Jordana Joy
March 20, 2025By Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment. Nora Lee Cothran, OD, FAAO, discussed a real-world study on switching glaucoma patients to latanoprostene bunod (LBN). Cothran explained that she initially noticed good pressure-lowering results when switching patients to LBN in her clinical practice.
-
1 month ago | 
optometrytimes.com | Emily Kaiser Maharjan
Harrow has announced a new initiative, VEVYE Access for All, in hopes of removing obstacles to dry eye therapy via a partnership with PhilRx, a national mail-order pharmacy partner, which will help expedite prescription fulfillment with no prior authorization and flat-rate refill program. This program is in place for prescriptions of cyclosporine ophthalmic solution 0.1% (VEVYE, Harrow) and promises a $59 price tag per bottle, effective immediately.
-
1 month ago | 
optometrytimes.com | Mile Brujic |Emily Kaiser Maharjan
Enhancing paraoptometric training: A view behind the slit lampMile Brujic, OD, FAAO, recently delivered a series of courses at SECO, which took place February 26 through March 2, 2025 in Atlanta, Georgia. One of these was focused on paraoptometric education. The goal was to provide support staff with a deeper understanding of what optometrists observe behind the slit lamp—something that is fundamental to patient care but often unseen by assistants.
-
1 month ago | 
ophthalmologytimes.com | Emily Kaiser Maharjan
NewsArticleMarch 11, 2025Author(s):The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation. The FDA has accepted the New Drug Application (NDA) submitted by Sydnexis for SYD-101, a low-dose atropine drop indicated for myopia management, with a Prescription Drug User Fee Act (PDUFA) target action date set for October 23, 2025.
-
1 month ago | 
optometrytimes.com | Stephanie L. Woo |Emily Kaiser Maharjan
The CRU Eye Symposium, short for Current, Relevant, Useful, is an upcoming CE-accredited conference designed specifically for optometrists and held in Napa Valley, California, to make use of its beautiful setting and bountiful wine selection.
